NAGE Niagen Bioscience, Inc.
Niagen Bioscience, Inc. operates as a bioscience company engages in developing healthy aging products. The company operates through Consumer products; Ingredients; and Pharmaceutical Segments. It provides finished dietar…
Industry Peers
Packaged Foods| Headline | Source | Time |
|---|---|---|
Older | ||
 Niagen Bioscience (NAGE): Can Its NAD+ Business Drive the Next Leg of Growth? Gabelli Investment Management Firm recently released its “Mini Mites Fund” second-quarter 2026 investor letter. A copy of the letter can be downloaded here. The Fund benefited from a strong investment environment for global small- and micro-cap stocks in the second quarter of 2026, as AI adoption, reshoring, supply-chain reconfiguration, and strength in semiconductor, aerospace, defense, […] | ||
 Does Niagen Bioscience's (NAGE) Walmart NAD+ Push Redefine Its Healthy‑Aging Brand Narrative? In early August 2026, Niagen Bioscience Inc. reported slightly lower quarterly sales and net income year on year, while also expanding access to its Tru Niagen® healthy‑aging NAD+ supplement via Walmart.com, initially offering 300 mg bottles in 30‑ and 90‑count formats. A new peer‑reviewed analysis in Aging Cell linked Niagen’s nicotinamide riboside supplementation to reduced muscle epigenetic age acceleration, adding scientific depth to its healthy‑aging positioning just as distribution... | ||
Niagen Bioscience (NAGE) On New Aging Study And The Case For A Higher Fair Value Niagen Bioscience (NAGE) is back in focus after a new peer reviewed study reported that its Niagen nicotinamide riboside supplementation was associated with reduced muscle epigenetic age acceleration compared with exercise based protocols. See our latest analysis for Niagen Bioscience. The recent clinical findings arrive after a difficult stretch for Niagen Bioscience’s stock. The 1 day share price return has fallen 14.7% and the year to date share price return has declined 52.64%. However,... | ||
Niagen Bioscience Inc (NAGE) (Q2 2026) Earnings Call Highlights: E-Commerce Surge and China ... Niagen Bioscience Inc (NAGE) reports strong TrueNiagen sales growth, China cross-border revenue exceeding full-year 2025 totals, and advances in pharmaceutical pipeline with promising PRV potential. | ||
 Niagen Bioscience (NAGE) Meets Q2 Earnings Estimates Niagen Bioscience (NAGE) delivered earnings and revenue surprises of 0.00% and -0.55%, respectively, for the quarter ended June 2026. Do the numbers hold clues to what lies ahead for the stock? | ||